Color Health vs Helix
Helix holds the stronger position because its patient-data partnerships are expanding while Color Health has faced valuation swings and layoffs.
Color Health
Virtual cancer clinic with genetic testing and oncologist-led care, sold through employers and health plans
Helix
Helix runs population genomics tests and licenses linked clinical-genomic data to health systems and drug makers
Dimension by dimension
| Dimension | Color Health | Helix |
|---|---|---|
| Staying power of the core product | Color Health sells virtual cancer care and genetic testing through employer and health plan contracts, the same channel several rivals are chasing. | Helix links clinical genomic sequencing to drug-maker licensing deals, backed by 16 health system partners and over 500,000 linked records with a stated goal of reaching 1 million. |
| Exposure to AI absorbing the product | Oncologist-led virtual cancer care is also described as unlikely to be absorbed by AI. | Population-scale genomic sequencing and data licensing are described as unlikely to be swallowed by AI tools. |
| How easily a giant could copy them | A large player could possibly replicate Color Health's virtual clinic model too. | A large player could possibly replicate Helix's sequencing and licensing model. |
| Pressure from rivals | Thyme Care, AccessHope, and Included Health sell nearly identical virtual-oncology navigation into the same employer contracts Color depends on. | Tempus and GeneDx compete for the same pharma-licensing and health-system data deals, but no documented Helix customer loss exists. |
| Financial footing | Color Health's disclosed valuation dropped from $4.6B to $1.5B between late 2021 and early 2021, and it laid off 300 employees in 2023. | Helix reports steady growth numbers, including an explicit target of doubling its linked records within 18 months. |
| Business model differentiation | Color Health's care-navigation model overlaps closely with several employer-benefit competitors selling similar services. | Helix's data-licensing tie to drug makers gives it a distinct role beyond direct care delivery. |
Questions people ask
- Is Helix or Color Health more exposed to AI replacing what they do
- Neither company looks likely to have its core product absorbed by AI. Helix's genomic sequencing and data licensing and Color Health's oncologist-led virtual care both rely on activities marked unlikely to be automated away.
- Which company faces tougher competition, Helix or Color Health
- Color Health faces tougher competition because Thyme Care, AccessHope, and Included Health are selling very similar virtual-oncology services into the same employer contracts. Helix also has rivals in Tempus and GeneDx, but no customer loss has been documented.
- How do Helix and Color Health compare financially
- Helix shows growth signals, including a rising count of linked patient records and an explicit expansion target. Color Health has seen its valuation reported as falling sharply between 2021 measurements and cut 300 jobs in 2023.
- Could a big tech company copy Helix or Color Health
- Both are marked as possible to copy by a larger player. Neither company's setup is described as fully protected from a well-resourced competitor entering the space.
- Which company has a stronger position overall, Helix or Color Health
- Helix appears stronger right now because its partnership and data numbers are growing while Color Health has reported valuation declines and layoffs. Both still carry the same moat and pressure scores on the broader scale.
Other comparisons with these companies